13 results
ARS
2024 FY
CCCC
C4 Therapeutics Inc
30 Apr 24
Annual report to shareholders
8:52am
expenses; the costs of laboratory supplies and acquiring materials for preclinical studies and clinical trials; the costs associated with wind down … and other current liabilities $ 20,630 $ 19,769 As of December 31, 2023 there were $3.1 million of costs related to wind down activities for CFT8634
8-K
EX-99.1
CCCC
C4 Therapeutics Inc
1 Nov 23
C4 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
7:18am
with CFT8634 as a single agent. No additional patients will be enrolled in the CFT8634 Phase 1 trial and wind down activities are expected to be complete
8-K
EX-10.1
CCCC
C4 Therapeutics Inc
30 May 23
Entry into a Material Definitive Agreement
7:30am
this Section 13.3(d)(i) to C4T.
(ii)Licensee shall have the right to elect in its sole discretion to, (A) wind-down any ongoing Development
S-1
EX-10.11
ysmazmlmr
10 Sep 20
IPO registration
5:26pm
S-1
EX-10.13
maylr0bvwe8im7litl
10 Sep 20
IPO registration
5:26pm
S-1
EX-10.12
1vmw8xnjtzlx4
10 Sep 20
IPO registration
5:26pm
S-1
EX-3.1
i5y ejjmz9
10 Sep 20
IPO registration
5:26pm
DRS
EX-10.6
rpaq26ru
6 Aug 20
Draft registration statement
12:00am
DRS
EX-10.7
l24bu4eihd cc
6 Aug 20
Draft registration statement
12:00am
DRS
EX-10.8
nd41pq3iz21jgwdzhht
6 Aug 20
Draft registration statement
12:00am
DRS
EX-3.1
2xq7zhjn
6 Aug 20
Draft registration statement
12:00am
- Prev
- 1
- Next